NOVARTIS for NOVARTIS
What was lobbied
11 issue areas, each in the filer's own words, with who lobbied on it and where.
Science/Technology SCI
Artificial intelligence Data and digital technologies
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SARAH HALLER | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Labor Issues/Antitrust/Workplace LBR
Anti-Trust Reform The Competition and Antitrust Law Enforcement Reform Act (S.225):
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Trade (domestic/foreign) TRD
Access to Medicines Issues Biopharmaceutical Innovation Policies China Agreement Free Trade Agreements - Intellectual Property and Transparency Provisions Global Health Issues India, China and Canada IP and Market Access Issues Intellectual property International Market Access and Intellectual Property Issues Pharmaceutical Supply Chain Pricing and reimbursement policy issues Quality of Medicines Regulatory Cooperation Supply chain and China Task Force policy issues Tariffs Trade Policy USTR Special 301 Report/National Trade Estimate WTO IP Waiver
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Taxation/Internal Revenue Code TAX
ACA Pharmaceutical Industry Fee Administration's FY 2022 Revenue Proposals Base Erosion Anti-Abuse Tax (BEAT) OECD Digital Tax Orphan Drug Tax Pharmaceutical supply chain incentives R&D Amortization Restrict deductions of excessive interest of members of financial reporting groups for disproportionate borrowing in the United States (Sec. 163(n) & 163(o)) Stopping Harmful Inversions and Ending Low-Tax Developments (SHIELD) Tax Treatries Thin Capitalization Rules 163(j) U.S. Corporate Tax
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Copyright/Patent/Trademark CPT
Antitrust Legislation Bayh-Dole Act Biopharmaceutical Intellectual Property Biosimilars BPCIA Compulsory licenses Data Exclusivity H.R. 2873, Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 Intellectual Property Issues in Reponse to coronavirus Inter Partes Review at PTO Patent Litigation Reform and Issues Related to Post Grant Proceedings at PTO Patents S.1435, Affordable Prescriptions for Patients Act of 2021 S.225, Competition and Antitrust Law Enforcement Reform Act Section 101 H.R. 2883, the Stop Stalling Access to Affordable Medications H.R. 2891, the Preserve Access to Affordable Generics and Biosimilars Act H.R. 2873, the Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R. 2884, the Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act 35 USC Section 101 on Patent Eligibility
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Health Issues HCR
21st Century Cures Act 2.0 340B Drug Discount Program Advanced Research Projects Agency for Health (ARPA-H) AMP Cap Biosimilar approval and reimbursement policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions BLOCKING Act Buy American and other associated issues related to procurement and sourcing of finished product and active pharmaceutical ingredients Cell, gene and radioligand therapies Comprehensive Immunosuppressant Drug Coverage for Kidney Transplant Patients Act of 2020 Co-pay accumulator programs COVID-19 Defense Production Act Diversity in Clinical Trials Drug cost and pricing policy issues Drug Importation and conterfeiting policy issues Drug shortages policy issues Drug vial size policy issues FDA modernization policy issues Foreign manufacturing policy issues Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement FY 2022 Labor-HHS Appropriations H.R.1319, American Rescue Plan Act of 2021 H.R.133, Consolidated Appropriations Act for FY 2021 H.R.2815, The BIOSIM Act H.R.2855, Star Rating for Biosimilars Act H.R.3, Elijah E. Cummings Lower Drug Costs Now Act H.R.5463, Drug Pricing Transparency and Accountability Act H.R. 5260, Reduced Costs and Continued Cures Act H.R. 4811, Medicare Negotiation and Competitive Licensing Act of 2021 Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Medicaid Generics Penalty Fix Medicaid Payment Reform Notice of Benefit Payment Parameters (NBPP) Orphan Drugs Outcomes based contracting/value based arrangements Part B Home Infusion Patient assistance program policy issues PDUFA, BSUFA, GDUFA Pharmaceutical quality Pharmaceutical supply chain H.R.5388/S.2740 PREPARE ACT of 2021 (API stockpiling) Priority Review Voucher (PRV) Regulatory efficiencies policy issues S.1427, HR 2869 - Increasing Access to Biosimilars Act of 2021 S.164, Advancing Education on Biosimilars Act of 2021 Transparency policy issues Vaccines White House National Biodefense Strategy H.R. 5416, The Give Kids a Chance Act Healthcare Disparities R&D Funding for Medical Countermeasures Reference Pricing in Drug Reimbursement Senate Finance Committee Drug Pricing Principles Senate HELP Pandemic Preparedness White Paper Step Therapy
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Veterans VET
Health care collaboration opportunities
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| JOSEPH MCGOWAN | — |
| COURTNEY PIRON | — |
Foreign Relations FOR
CFIUS Reform Foreign Agents Registration Act (FARA) Reform
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| LEO A FARBER | — |
| SHELLY MUI-LIPNIK | — |
| COURTNEY PIRON | — |
Medicare/Medicaid MMM
AMP Cap Anti-Kickback Statute policy issues ASP reporting policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues Department of Health and Human Services (HHS) drug policy issues and regulatory policy issues Drug Pricing Drug wastage rebates policy issues Innovative Pharmaceuticals (including cell, gene and radioligand therapies), Biosimilars and Generics Medicaid Medicaid rebates and waiver policy issues Medicare Part A, B and D Outcomes based Contracting/value based arrangements Patient Cost-Sharing and Smoothing Reimbursement for cell therapy products Removal of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals Transparency policy issues S.2911, Seniors Prescription Drug Relief Act of 2019 Medicare Negotiations Inflation penalties in Medicare Part B and Part D Part D Benefit Redesign
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Budget/Appropriations BUD
Advanced Research Projects Agency for Health (ARPA-H) Biosimilars Drug Pricing Fiscal year 2022 Appropriations Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement H.R.1, For the People Act of 2021 H.R.1319, American Rescue Plan Act of 2021 H.R.133, Consolidated Appropriations Act for FY 2021 H.R.5376, Build Back Better Act Importation National Defense Authorization Act FY 2022 Prescription Drug User Fee Act (PDUFA) VII Priorities Value of Medicine Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations act for FY 2020 Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020 Health Defense Operations Funding Designation Implementation of the Prescription Drug User Fee Act (PDUFA) VI
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| SARAH HALLER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
| SHELLY MUI-LIPNIK | — |
| SEEMIN PASHA | — |
| COURTNEY PIRON | — |
Energy/Nuclear ENG
Increasing domestic supply of Actinium 225 Climate Change Environmental sustainability and climate change issues Climate risk disclosures
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TAYLOR BOOTH | — |
| NORA CONNORS | — |
| LEO A FARBER | — |
| COURTNEY LEE-ASHLEY | — |
| JOSEPH MCGOWAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.